fashion -WSS

fashion

author：leisure time 2025-09-27 10:03:35 - browse：57925

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： HIV vaccine remains elusive. Immunologists keep trying new ideas

WSS

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Venture capitalist Bob Kocher on the state of digital health

New chief aims to remake Sanofi Genzyme

HIV vaccine remains elusive. Immunologists keep trying new ideas

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Readers respond to H5N1 and livestock movements, and more

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Solving academic medical centers' existential crisis

Trump demands the U.S. pay no more for drugs than other countries … again

The biotech scorecard for the 2nd quarter: 12 industry events to watch

23andMe had bad news about my health. I wish a person had delivered it

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

Hollywood unions extend contract negotiations for actors

Cytokinetics CEO stresses company can launch heart drug on its own

Trump demands the U.S. pay no more for drugs than other countries … again

With measles on the rise, a personal story of a devastating disease

leisure time

Addiction experts warn against a second 'war on drugs'

EMA weighs against approval for Mirati's lung cancer drug

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

'The View' co

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

focus

entertainment

hotspot

focus